Young Suk Park
Hallym University
4 Papers
54 Citations
Young Suk Park is an academic researcher from Hallym University. The author has contributed to research in topics: Renal function & Multicenter trial. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients
Chul Won Choi,Byung Soo Kim,Jae Hong Seo,Sang Won Shin,Yeul Hong Kim,Jun Suk Kim,Sang Kyun Sohn,Jae Seok Kim,Dong Gun Shin,Hun Mo Ryoo,Kyung Hee Lee,Je-Jung Lee,Ik Joo Chung,Hyeoung Joon Kim,Jae Yong Kwak,Chang Yeol Yim,Jin Seok Ahn,Jung Ae Lee,Young Suk Park +18 more
TL;DR: The results indicate that the response to high‐dose IVIG could be a valuable factor predicting the sustained response to splenectomy in chronic ITP patients.
41
High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.
Soo Mee Bang,Eun Kyung Cho,Cheolwon Suh,Sung-Soo Yoon,Chu Myung Seong,Kyung Sam Cho,Yoon-Goo Kang,Seonyang Park,Myung Ju Ahn,Young Suk Park,Doyeun Oh,Hugh C. Kim,Chul Won Jung,Samyong Kim,Jae Hoon Lee +14 more
TL;DR: This study verifies the efficacy and feasibility of high dose melphalan therapy with autologous stem cell transplantation in newly diagnosed multiple myeloma.
Two cases of Ticlopidine-induced neutropenia in patients with cardiovascular disease
Gyeong Soo Chae,Hee Seung Yoo,Jae Hwan Jee,Jong Min Lee,Jin Seok Ahn,Jung Ae Lee,Young Suk Park,Young Cheoul Doo,Kyoo Rok Han,Dong Jin Oh,Chong Yun Rhim +10 more
TL;DR: Because ticlopidine causes neutropenia and agranulocytosis in roughly 1% of treated patients, usually within the first 3 months of treatment, this drug has been reserved for patients intolerant to aspirin therapy.
4